Nautilus reveals the setup and testing of its external field evaluation unit.
Nautilus Biotechnology's Achievement: Nautilus Biotechnology successfully installed and tested its first external field evaluation unit, generating reproducible data from neurodegenerative disease samples over six months.
Collaboration with Buck Institute: The collaboration with the Buck Institute aims to utilize the Nautilus Proteome Analysis Platform to investigate tau proteoforms related to Alzheimer's and neurodegeneration.
Future Reporting: Initial findings from this research will be presented at the 2025 Human Proteome Organization World Congress.
Joint Publication Plans: There are plans for future joint publication efforts based on the research outcomes from the collaboration.
Trade with 70% Backtested Accuracy
Analyst Views on NAUT

No data
About NAUT
About the author

VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.







